Article
Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis.
PLoS genetics - 1 Mar 2013
Cui Jing, Stahl Eli A, Saevarsdottir Saedis, Miceli Corinne, Diogo Dorothee, Trynka Gosia, Raj Towfique, Mirkov Maša Umiċeviċ, Canhao Helena, Ikari Katsunori, Terao Chikashi, Okada Yukinori, Wedrén Sara, Askling Johan, Yamanaka Hisashi, Momohara Shigeki, Taniguchi Atsuo, Ohmura Koichiro, Matsuda Fumihiko, Mimori Tsuneyo, Gupta Namrata, Kuchroo Manik, Morgan Ann W, Isaacs John D, Wilson Anthony G, Hyrich Kimme L, Herenius Marieke, Doorenspleet Marieke E, Tak Paul-Peter, Crusius J Bart A, van der Horst-Bruinsma Irene E, Wolbink Gert Jan, van Riel Piet L C M, van de Laar Mart, Guchelaar Henk-Jan, Shadick Nancy A, Allaart Cornelia F, Huizinga Tom W J, Toes Rene E M, Kimberly Robert P, Bridges S Louis, Criswell Lindsey A, Moreland Larry W, Fonseca João Eurico, de Vries Niek, Stranger Barbara E, De Jager Philip L, Raychaudhuri Soumya, Weinblatt Michael E, Gregersen Peter K, Mariette Xavier, Barton Anne, Padyukov Leonid, Coenen Marieke J H, Karlson Elizabeth W, Plenge Robert M
Abstract excerpt
Anti-tumor necrosis factor alpha (anti-TNF) biologic therapy is a widely used treatment for rheumatoid arthritis (RA). It is unknown why some RA patients fail to respond adequately to anti-TNF therapy, which limits the development of clinical biomarkers to predict response or new drugs to target refractory cases. To understand the biological basis of response to anti-TNF therapy, we conducted a genome-wide...
Read the complete abstract on PubMed